Frontage Holdings Corporation (Frontage) released its 2026 interim results, showing double-digit top-line growth and a sharp rebound in profitability for the six months ended 30 June 2026.
Revenue and Profitability • Group revenue advanced 17.1 % year on year to USD 148.19 million, led by higher laboratory testing (+26.9 %) and drug development services (+12.0 %). • Gross profit increased 7.4 % to USD 37.90 million; gross margin eased to 25.6 % (1H25: 27.9 %) due to an unfavourable service mix and higher costs in North America and Europe. • Reported net profit jumped 132.4 % to USD 6.79 million, lifting net margin to 4.6 % (1H25: 2.3 %). • Adjusted net profit—excluding share-based payments, M&A-related amortisation and one-off items—rose 74.0 % to USD 13.44 million, equating to an adjusted margin of 9.1 % (1H25: 6.1 %). • Basic and diluted EPS doubled to USD 0.0033; adjusted diluted EPS improved 73.7 % to USD 0.0066.
Regional Performance • North America & Europe: Revenue up 7.8 % to USD 106.30 million, supported by robust demand for laboratory testing. Segment gross margin slipped to 27.3 % (1H25: 30.4 %). • China: Revenue up 43.6 % (RMB terms) to RMB 288.4 million (USD 41.90 million), boosted by the March 2026 acquisition of Teddy Clinical Research Laboratory (Shanghai) Ltd (Teddy Lab). Gross margin improved to 21.3 % (1H25: 19.2 %).
Operational Highlights • Completed acquisition of Teddy Lab for RMB 270 million (USD 39.00 million), adding central-laboratory capabilities in pathology, flow cytometry and molecular biology. Goodwill recognised: USD 9.98 million. • Order backlog (contract future revenue) expanded 34.2 % year on year to USD 543.20 million. • Continued investment in AI-assisted workflows and laboratory automation; expansion of sterile manufacturing to 400-litre batch capacity and 10,000-vial fill-finish scale. • Added NULISA proteomics platform, CLIA-based laboratory-developed tests, and Hamilton automation systems in biomarker and biologics divisions.
Cash Flow and Balance Sheet • Operating cash inflow reached USD 25.66 million (1H25: USD 18.76 million). • Capital expenditure totalled USD 6.23 million, focused on facility upgrades and equipment. • Cash and cash equivalents stood at USD 34.56 million (31 Dec 2025: USD 36.30 million). • Net debt increased to USD 61.43 million; gearing ratio rose to 29.2 % (FY25: 25.4 %), reflecting higher borrowings of USD 96.0 million, partly funding the Teddy Lab acquisition. • Total assets reached USD 580.47 million; equity expanded to USD 356.23 million.
Other Financial Metrics • EBITDA grew 17.4 % to USD 31.70 million; EBITDA margin steady at 21.4 %. • Adjusted EBITDA advanced 22.8 % to USD 34.46 million, lifting margin to 23.3 %. • Research & development spend up 36.4 % to USD 3.04 million, reflecting integration of new capabilities. • Selling and marketing expenses fell 7.0 % to USD 3.96 million; administrative expenses down 9.1 % to USD 18.91 million after excluding one-offs. • Finance costs eased 16.7 % to USD 3.49 million following refinancing and loan repayments.
Dividend and Outlook The Board declared no interim dividend. Management cites a market outlook projecting the global CRO industry to reach USD 199.28 billion by 2034 (CAGR 9.0 %) and plans to pursue further capability expansion, AI adoption and selective acquisitions.
Post-Period Events The Board reported no material events after 30 June 2026 up to the report date.